5,422 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Asia markets in red tracking sharp selloff on Wall Street ahead of key US jobs report; oil soars https://seekingalpha.com/news/4087451-asia-markets-in-red-tracking-sharp-selloff-on-wall-street-ahead-of-key-us-jobs-report-oil-soars?source=feed_tag_india Apr 05, 2024 - Japan (NKY:IND) -1.96%. Household spending in Japan dropped in real terms by 0.5% year over year in February 2024, less than market forecasts of a 3.0% fall.
India Keeps Key Interest Rates Unchanged https://www.rttnews.com/3437108/india-keeps-key-interest-rates-unchanged.aspx?type=alleco Apr 04, 2024 - India's central bank decided to retain its key interest rates on Friday, as inflation is on a declining trajectory.
Afya (AFYA) Suffers a Larger Drop Than the General Market: Key Insights https://www.zacks.com/stock/news/2250772/afya-afya-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2250772 Apr 04, 2024 - The latest trading day saw Afya (AFYA) settling at $18.13, representing a -1.47% change from its previous close.
DXP Enterprises (DXPE) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2250746/dxp-enterprises-dxpe-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2250746 Apr 04, 2024 - In the most recent trading session, DXP Enterprises (DXPE) closed at $54.59, indicating a +0.76% shift from the previous trading day.
Cadence Design Systems (CDNS) Suffers a Larger Drop Than the General Market: Key Insights https://www.zacks.com/stock/news/2250747/cadence-design-systems-cdns-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2250747 Apr 04, 2024 - Cadence Design Systems (CDNS) concluded the recent trading session at $306.48, signifying a -1.32% move from its prior day's close.
RPM International (RPM) Reports Q3 Earnings: What Key Metrics Have to Say https://www.zacks.com/stock/news/2250431/rpm-international-rpm-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2250431 Apr 04, 2024 - The headline numbers for RPM International (RPM) give insight into how the company performed in the quarter ended February 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conagra Brands (CAG) Reports Q3 Earnings: What Key Metrics Have to Say https://www.zacks.com/stock/news/2250430/conagra-brands-cag-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2250430 Apr 04, 2024 - The headline numbers for Conagra Brands (CAG) give insight into how the company performed in the quarter ended February 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About Lindsay (LNN) Q2 Earnings https://www.zacks.com/stock/news/2250429/here-s-what-key-metrics-tell-us-about-lindsay-lnn-q2-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2250429 Apr 04, 2024 - Although the revenue and EPS for Lindsay (LNN) give a sense of how its business performed in the quarter ended February 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unveiling Tilray Brands (TLRY) Q3 Outlook: Wall Street Estimates for Key Metrics https://www.zacks.com/stock/news/2250388/unveiling-tilray-brands-tlry-q3-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2250388 Apr 04, 2024 - Besides Wall Street's top -and-bottom-line estimates for Tilray Brands (TLRY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended February 2024.
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526 Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
<<<Page 301>